Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Web Exclusives
Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Read More
Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Read More
Lung Cancer
Unmet Needs in NSCLC
Read More
Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Read More
Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy
Read More
Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Read More
Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Read More
Meeting Highlights
AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Read More
Meeting Highlights
AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Read More
7
8
9
10
11
12
13
Page 10 of 42
Results 91 - 100 of 417